238 related articles for article (PubMed ID: 31913293)
1. Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study.
Lee BH; Kang KW; Jeon MJ; Yu ES; Kim DS; Choi H; Lee SR; Sung HJ; Kim BS; Choi CW; Park Y
Sci Rep; 2020 Jan; 10(1):39. PubMed ID: 31913293
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G
Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
Zhang YP; Wu WZ; Cui GX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1341-4. PubMed ID: 25338585
[TBL] [Abstract][Full Text] [Related]
5. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
[TBL] [Abstract][Full Text] [Related]
6. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study.
Hu N; Qin T; Du X; Wang B; Wang X; Xu Z; Pan L; Qu S; Xiao Z
Med Sci Monit; 2021 Jan; 27():e928454. PubMed ID: 33514682
[TBL] [Abstract][Full Text] [Related]
8. Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study.
Wu D; Du X; Jin J; Xiao Z; Shen Z; Shao Z; Li X; Huang X; Liu T; Yu L; Li J; Chen B; He G; Cai Z; Liang H; Li J; Ruan C
Adv Ther; 2015 Nov; 32(11):1140-59. PubMed ID: 26568466
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.
Lee YG; Kim I; Yoon SS; Park S; Cheong JW; Min YH; Lee JO; Bang SM; Yi HG; Kim CS; Park Y; Kim BS; Mun YC; Seong CM; Park J; Lee JH; Kim SY; Lee HG; Kim YK; Kim HJ;
Br J Haematol; 2013 May; 161(3):339-47. PubMed ID: 23432512
[TBL] [Abstract][Full Text] [Related]
10. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
11. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.
Steensma DP; Baer MR; Slack JL; Buckstein R; Godley LA; Garcia-Manero G; Albitar M; Larsen JS; Arora S; Cullen MT; Kantarjian H
J Clin Oncol; 2009 Aug; 27(23):3842-8. PubMed ID: 19528372
[TBL] [Abstract][Full Text] [Related]
12. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Kantarjian HM; O'Brien S; Huang X; Garcia-Manero G; Ravandi F; Cortes J; Shan J; Davisson J; Bueso-Ramos CE; Issa JP
Cancer; 2007 Mar; 109(6):1133-7. PubMed ID: 17315156
[TBL] [Abstract][Full Text] [Related]
13. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Xie M; Jiang Q; Xie Y
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
Wu L; Li X; Chang C; Xu F; He Q; Wu D; Zhang Z; Su J; Zhou L; Song L; Chao X; Zhao Y
Leuk Lymphoma; 2016; 57(6):1367-74. PubMed ID: 26397697
[TBL] [Abstract][Full Text] [Related]
15. A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome.
Jeong SH; Kim YJ; Lee JH; Kim YK; Kim SJ; Park SK; Do YR; Kim I; Mun YC; Kim HG; Lee WS; Yi HG; Joo YD; Choi CW; Kim SR; Na SM; Jang JH
Oncotarget; 2015 Dec; 6(42):44985-94. PubMed ID: 26517692
[TBL] [Abstract][Full Text] [Related]
16. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
17. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
18. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Baek DW; Lee YJ; Kim H; Ahn SY; Ahn JS; Shin HJ; Lee WS; Lee SM; Song IC; Lee HS; Park SW; Choi Y; Cho YY; Bae SH; Kim HJ; Sohn SK; Moon JH
Ann Hematol; 2018 Dec; 97(12):2309-2317. PubMed ID: 30073392
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
[TBL] [Abstract][Full Text] [Related]
20. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]